ArticleTargeted oncology2017
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.
Zev A Wainberg et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
66 papers cite itlatest 60 shown
this papertrialcites it